stronger warning about potential hepatotoxicity in patients taking Duract (bromfenac)

April 1998

The FDA is requiring a stronger warning about potential hepatotoxicity in patients taking Duract (bromfenac).

Duract is the new NSAID that just came out last fall. It's approved only for SHORT-TERM use...similar to Toradol (ketorolac).

Now there are several reports of severe hepatitis and liver failure in patients taking Duract for longer than a month.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote